Amber Salzman: Epigenetic Editing Aims to Refine Personalized Genetic Medicine
Update: 2025-07-23
Description
With recent safety setbacks in gene therapy underscoring the risks of genetic medicine, Amber Salzman, PhD, is charting a different course. After 25 years in big pharma, she now leads Epicrispr, where their Gene Expression Modulation System (GEMS) fine-tunes gene activity to tackle diseases too complex for traditional gene replacement, including Duchenne muscular dystrophy. On Behind the Breakthroughs, Salzman shares how epigenomic modulation could open new frontiers in treatment.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by David Mosely
Brought to you by Inside Precision Medicine (SAGE Publishing)
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
